Aurobindo Pharma Limited

Aurobindo Pharma Limited ("Aurobindo") is an India-based, vertically integrated pharmaceutical manufacturer incorporated in 1986 and headquartered in Hyderabad, Telangana. It is publicly listed on the National Stock Exchange and BSE (ticker: AUROPHARMA) and is not a subsidiary of any larger group. FY2026 revenue was roughly ₹33,650 crore (about US$3.8 billion) with EBITDA of about ₹6,850 crore; market capitalization was approximately ₹96,000 crore (≈US$9–9.5 billion) in mid-2026. Reported headcount is roughly 27,700–29,200 employees (FY2026); some third-party databases list higher figures, and counts vary by source.

Products and operations. Aurobindo develops, manufactures and sells generic formulations and active pharmaceutical ingredients (APIs). Formulations are the large majority of revenue, split mainly across US oral solids and injectables (about 44% of sales), Europe (about 30%), growth markets including India, and anti-retroviral (ARV) products; APIs account for roughly 11–13%. Therapeutic areas include CNS, cardiovascular, antibiotics, gastroenterology, anti-diabetics, anti-allergics and ARVs. It has expanded into complex injectables, oncology oral solids, biosimilars and biologics CMO through subsidiaries including Eugia Pharma Specialities, CuraTeQ Biologics, Lyfius Pharma and TheraNym, and operates manufacturing and R&D sites in India, the US, Brazil, Portugal, China and Puerto Rico. It is an operating company, not a patent assertion entity.

Litigation posture. The tracked data show Aurobindo solely as a defendant (0 plaintiff cases, 1 defendant case), which is consistent with a generic manufacturer responding to Hatch-Waxman/ANDA suits brought by brand holders. The single tracked matter, Merck Sharp & Dohme Corp. v. Aurobindo Pharma Limited, was filed in the U.S. District Court for the District of Delaware — a common venue for ANDA litigation — not a plaintiff-friendly NPE venue such as the Eastern District of Texas.

Notable case and context. The tracked Delaware suit (D. Del. No. 1:25-cv-00449, filed April 2025) concerned U.S. Patent 7,326,708 and Aurobindo's ANDA for a generic version of Janumet XR (sitagliptin); the docket shows a negotiated consent judgment and injunction entered in July 2025. Aurobindo has also litigated Merck's BRIDION (sugammadex) reissue patent, which produced the Federal Circuit's 2025 Merck v. Aurobindo decision on patent term extension calculation. Other tracked docket detail beyond the single case above was not verified.